TRIM66

Across TCGA pan-cancer cohorts, TRIM66 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated TRIM66 data layer compared with 21 for mass-spec protein.

The strongest signal is observed in testicular germ cell tumors (TGCT), where higher TRIM66 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated TRIM66 expression acts as an unfavorable survival marker.

TGCT and SARC are the cancer types where TRIM66 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
TGCT	DFS	Median	All	0.035	0.837	<.001	6	view →
SARC	DFS	Median	All	0.121	0.591	.042	3	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

TRIM66–TGCT (DFS)

Open the TGCT breakdown →